Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Amber Bio logo — Rewriting the Rules of Medicine

Amber Bio

Rewriting the Rules of Medicine

Founded 2022 20 employees Seed Total: $26.00M Biotechnology, Pharmaceutical

General Information

Company Name Amber Bio
Founded Year 2022
Employees 20
Industries Biotechnology, Pharmaceutical
Funding Stage Seed
Social

Get notified when Amber Bio moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Amber Bio

Amber Bio is a biotechnology startup with the slogan "Rewriting the Rules of Medicine." Founded in 2022, the company is pioneering new gene editing modalities using multi-kilobase edits to reach previously undruggable patient populations. Their approach challenges the current paradigm in genetic medicine, which relies on developing independent therapies for each separate mutation in the patient population. The company, founded by pioneers in the CRISPR field from leading institutions for gene editing research, is developing a first-of-its-kind RNA writing platform capable of editing thousands of diverse mutations across patients with a single product. Amber Bio recently received a significant $26.00M Seed Round investment on 03 August 2023. The investment was made by a group of notable investors including Pillar, Andreessen Horowitz (a16z), Playground Global, SV Angel, Eli Lilly, Hummingbird Ventures, and Retinal Degeneration Fund. With their innovative approach and backing from prominent investors, Amber Bio is poised to make a considerable impact in the biotechnology and pharmaceutical industries. Their focus on addressing previously undruggable patient populations through advanced gene editing techniques positions them as a promising player in the field.

Taxonomy: gene editing, CRISPR, RNA writing, genetic medicine, therapies, mutation, undruggable patient populations, innovation, multi-kilobase edits, pioneering, precision medicine, biopharmaceuticals

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Round •••••• 7
Investor Investor Investor Investor Investor Investor Investor
03 Aug 2023

Amber Bio Alternatives & Competitors

Amber Bio vs
Epigenic Therapeutics
Epigenic Therapeutics China

Pioneering Epigenetic Medicine

Series A
13 employees
Biotechnology
Amber Bio vs
Excision BioTherapeutics
Excision BioTherapeutics United States

Developing CRISPR-based therapies intended to cure viral infectious diseases.

Grant
24 employees
Biotechnology, Health Care
Amber Bio vs
Modalis Therapeutics
Modalis Therapeutics United States

Modalis is an emerging biotech company that develops therapeutics using CRISPR based technology

IPO
23 employees
Biotechnology, Health Care

FAQ About Amber Bio

Rewriting the Rules of Medicine
Amber Bio was founded in 2022.
Amber Bio operates in the following industries: Biotechnology, Pharmaceutical.
Amber Bio has approximately 20 employees.
Amber Bio has completed 1 funding round, raising a total of $26.00M. The latest funding stage is Seed.
Top alternatives and competitors to Amber Bio include Epigenic Therapeutics, Excision BioTherapeutics, Modalis Therapeutics, GenEditBio Limited, Precision BioSciences, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Amber Bio and Epigenic Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Amber Bio and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes